Clal Insurance’s Takeda Pharmaceutical TAK Stock Holding History

Clal Insurance’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-45,000	Closed	-$625K	–	145
2024 Q1	$625K	Hold	45,000	–	–	0.01%	109
2023 Q4	$642K	Hold	45,000	–	–	0.01%	100
2023 Q3	$696K	Sell	45,000 -2,733,558	-98%	-$42.3M	0.01%	100
2023 Q2	$43.7M	Sell	2,778,558 -1,586,942	-36%	-$26M	0.52%	51
2023 Q1	$71.9M	Hold	4,365,500	–	–	1.08%	28
2022 Q4	$68.1M	Buy	4,365,500 +25,000	+0.6%	+$349K	1.02%	33
2022 Q3	$56.3M	Buy	4,340,500 +2,600,000	+149%	+$36.2M	0.77%	45
2022 Q2	$24.4M	Buy	+1,740,500	New	+$24.8M	0.33%	68

Other funds holding TAK

GAM

Groupama Asset Management Paris, France $7.93B AUM 57.28% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Clal Insurance's TAK Position: Q2 2024 in Review

Clal Insurance sold out of Takeda Pharmaceutical (TAK) in Q2 2024, closing a stake of 45,000 shares — an estimated $625K sold.

Clal Insurance first reported a position in TAK in Q2 2022 and held it in 8 quarters. The position peaked at $71.9M in Q1 2023. 284 funds tracked by Wall St. Rank hold TAK as of Q2 2024.

Clal Insurance reported no remaining Takeda Pharmaceutical position as of Q2 2024 after selling out during the quarter.
Clal Insurance sold 45,000 Takeda Pharmaceutical shares in Q2 2024, an estimated $625K.
Clal Insurance first reported a position in Takeda Pharmaceutical in Q2 2022 and held it in 8 quarters.
Clal Insurance's Takeda Pharmaceutical position peaked at $71.9M in Q1 2023.
284 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2024.

Based on Clal Insurance's 13F filing for Q2 2024, filed 14 Aug 2024.